Vivanza Biosciences Approves Q1 FY27 Results; TTM Revenue at Rs 116 Cr
Vivanza Biosciences approved its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company operates with a very small market capitalization of Rs 8 Cr and has shown significant revenue volatility, with the previous quarter (Mar 2026) seeing a sharp drop to Rs 6.36 Cr from Rs 45.25 Cr in Dec 2025. The board also confirmed director qualifications and independence as per statutory requirements. Investors should note the high debt-to-equity ratio of 2.50 and low promoter holding of 20.02%.
நடுத்தரம் நம்பிக்கை
என்ன மாறியதுThe board has officially approved and recorded the financial performance for the first quarter of the 2026-27 fiscal year.
ஏன் இது முக்கியம்For a micro-cap company with high debt and low promoter skin-in-the-game, quarterly results are critical to monitor liquidity and the ability to service its Rs 10 Cr debt.
TTM வருவாய்: Rs 116 கோடிசந்தை மதிப்பு: Rs 8 கோடிDebt-to-Equity Ratio: 2.50Promoter Holding: 20.02%Quarter Ended: 30th ஜூன், 2026
📅 குறுகிய காலம்The stock may remain range-bound given the micro-cap nature and the lack of immediate growth catalysts in the procedural announcement.
📈 நீண்ட காலம்The company's high leverage (D/E 2.50) and low operating margins (0.6%) suggest a high-risk profile unless consistent profitability is established.
⚠ அபாய எச்சரிக்கைகள்
- High debt-to-equity ratio (2.50)
- Low promoter holding (20.02%)
- Extreme quarterly revenue volatility
- Micro-cap liquidity risks
👀 கவனிக்க வேண்டியவை
Investors should examine the detailed P&L statement (Annexure A) to see if revenue has recovered from the low of Rs 6.36 Cr reported in the March 2026 quarter.
